Relay Therapeutics, a Cambridge, Mass-based company combining computing and biotechnology, has made a slew of senior appointments as it bolsters its R&D efforts.
Ben B Wold has joined as Chief Medical Officer; Mrunal ‘Monica’ Phadnis has been named as Vice President of Clinical Operations, and Iain Martin has joined as Vice President of Metabolism and Pharmacokinetics.
Dr Wolf is a precision oncologist who brings nearly 20 years of experience in the biopharma industry. He most recently served as Chief Medical Officer of KSQ Therapeutics.
Ms Phadnis is an end-to-end delivery expert with more than 15 years in clinical oncology research. Prior to joining Relay Therapeutics, she was the executive director of clinical development in oncology and haematology at Syneos Health.
Dr. Martin brings more than 30 years of experience in pharmaceutical drug metabolism and pharmacokinetics across therapeutic areas including oncology and neuroscience. Prior to joining Relay Therapeutics, he was executive director within the department of pharmacokinetics, pharmacodynamics and drug metabolism at Merck.
“As we advance multiple programs into the clinic in the coming year and continue to deepen our early stage pipeline, Ben’s extensive experience in clinical development and translational medicine, Monica’s background in clinical operations, and Iain’s expertise in drug discovery will be critical in helping propel the company in the next phase of our growth,” said Don Bergstrom, Executive Vice President and Head of R&D.